23 Feb uniQure
Benjamin Gaub, Ph.D., Business Development Director
April 15 | 1:45pm | Salone dei Cavalieri, Section 2
Amsterdam, Netherlands
(NASDAQ: QURE)
uniQure is delivering on the promise of gene therapy – a single treatment with curative results – through an innovative adeno-associated virus (AAV)-based technology platform supported by proprietary commercial-grade manufacturing. The recent approvals of our gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and usher in a new treatment approach for patients living with hemophilia. We’re now advancing a clinical program in Huntington’s disease with a growing list of preclinical candidates.
